ArticleLupus science & medicine2026
CD163: a potential biomarker for lupus nephritis activity.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCD163 is a macrophage-associated scavenger receptor shed during inflammatory activation, resulting in measurable soluble CD163 in serum (s) and urine (u). Elevated levels have been reported in inflammatory and immune-mediated conditions, including lupus nephritis (LN). This study aimed to investigate the relationship between soluble CD163 levels and intrarenal CD163 expression, evaluating their association with disease activity and treatment response in LN.
methodsForty-five patients with systemic lupus erythematosus (SLE) were included (20 active LN, 10 inactive LN, 15 active extra-renal SLE), together with 20 matched healthy controls. Serum and urine samples were collected at baseline alongside renal biopsy in active LN; 6-month follow-up samples were available for 12 active LN patients. CD163 was measured by ELISA; urinary CD163 was normalised to spot urine creatinine. Renal biopsies from 20 active LN patients were evaluated for CD163+ macrophage density.
resultsuCD163 was higher in active LN (a renal Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) flare (UPCR ≥0.5 g/g) with biopsy-proven active lesions) than in inactive LN and active extra-renal SLE (both p<0.001), discriminating active from inactive LN (area under the curve (AUC) 0.97) and from extra-renal SLE (AUC 0.89). uCD163 correlated with the National Institutes of Health activity and chronicity indices activity index (ρ=0.55, p=0.016) and with glomerular CD163+ macrophage density (the number of CD163+ macrophages per glomerulus quantified by immunohistochemistry; ρ=0.65, p=0.006), but not with chronicity. Glomerular CD163+ macrophage density also correlated with sCD163 (ρ=0.60, p=0.01) and uCD163 (ρ=0.63, p=0.009). After 6-month induction, uCD163 fell from 7.41 to 1.55 ng/mg (p<0.001).
conclusionuCD163 distinguishes active LN from inactive renal and extra-renal disease and tracks treatment response. The association with intrarenal CD163+ macrophages supports its biological relevance as a non-invasive marker of renal inflammation, complementary to histopathology when repeat biopsy is not feasible. These findings support uCD163 as a candidate non-invasive tool for identifying active LN and monitoring treatment response in SLE, warranting validation in larger prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.